Protagonist [PTGX] vs Axsome Therapeutics [AXSM] Detailed Stock Comparison

Protagonist Therapeutics Inc.

NASDAQ
Loading...

Axsome Therapeutics Inc.

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 19 vital metrics comparison: Protagonist Therapeutics Inc. wins in 8 metrics, Axsome Therapeutics Inc. wins in 10 metrics, with 0 ties. Axsome Therapeutics Inc. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Protagonist Therapeutics Inc. Axsome Therapeutics Inc. Better
P/E Ratio (TTM) 139.52 -50.54 Protagonist Therapeutics Inc.
Price-to-Book Ratio 10.79 105.31 Protagonist Therapeutics Inc.
Debt-to-Equity Ratio 1.68 247.03 Protagonist Therapeutics Inc.
PEG Ratio -1.05 0.79 Axsome Therapeutics Inc.
EV/EBITDA -39.56 -57.70 Protagonist Therapeutics Inc.
Profit Margin (TTM) -282.83% -28.69% Axsome Therapeutics Inc.
Operating Margin (TTM) -677.09% -18.38% Axsome Therapeutics Inc.
Return on Equity -20.18% -252.12% Protagonist Therapeutics Inc.
Return on Assets (TTM) -13.99% -16.81% Protagonist Therapeutics Inc.
Free Cash Flow (TTM) $56.08M $-93.89M Protagonist Therapeutics Inc.
1-Year Return 109.73% 122.97% Axsome Therapeutics Inc.
Price-to-Sales Ratio (TTM) 146.96 14.64 Axsome Therapeutics Inc.
Enterprise Value $6.21B $9.24B Axsome Therapeutics Inc.
EV/Revenue Ratio 134.85 14.47 Axsome Therapeutics Inc.
Gross Profit Margin (TTM) N/A 93.71% N/A
Revenue per Share (TTM) $1 $13 Axsome Therapeutics Inc.
Earnings per Share (Diluted) $-2.05 $-3.69 Protagonist Therapeutics Inc.
Beta (Stock Volatility) 2.11 0.47 Axsome Therapeutics Inc.
Short % of Float 16.13% 6.56% Axsome Therapeutics Inc.

Protagonist Therapeutics Inc. vs Axsome Therapeutics Inc. Stock Performance Analysis

Loading Price Chart...

PTGX
AXSM

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Protagonist Therapeutics Inc.2.34%-6.65%-4.13%4.50%10.85%9.44%
Axsome Therapeutics Inc.5.09%-0.45%4.37%42.32%57.95%30.66%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Protagonist Therapeutics Inc.109.73%253.05%186.01%760.50%760.50%760.50%
Axsome Therapeutics Inc.122.97%216.35%282.39%2,961.10%2,485.23%2,485.23%

Performance & Financial Health Analysis: Protagonist Therapeutics Inc. vs Axsome Therapeutics Inc.

MetricPTGXAXSM
Market Information
Market Cap i$6.76B$9.51B
Market Cap CategoryMid capMid cap
10 Day Avg. Volume i754,220592,425
90 Day Avg. Volume i902,710602,162
Last Close$95.41$233.47
52 Week Range$49.38 - $107.84$96.09 - $238.56
% from 52W High-11.53%-2.13%
All-Time High$106.90 (Apr 17, 2026)$238.56 (May 26, 2026)
% from All-Time High-10.75%-2.13%
Growth Metrics
Quarterly Revenue Growth-0.96%0.65%
Quarterly Earnings Growth-0.96%0.65%
Financial Health
Profit Margin (TTM) i-2.83%-0.29%
Operating Margin (TTM) i-6.77%-0.18%
Return on Equity (TTM) i-0.20%-2.52%
Debt to Equity (MRQ) i1.68247.03
Cash & Liquidity
Book Value per Share (MRQ)$9.82$1.74
Cash per Share (MRQ)$8.89$6.31
Operating Cash Flow (TTM) i$57.67M$-93,405,000
Levered Free Cash Flow (TTM) i$105.62M$-29,420,876
Dividends
Last 12-Month Dividend Yield iN/AN/A
Last 12-Month Dividend iN/AN/A

Valuation & Enterprise Metrics Analysis: Protagonist Therapeutics Inc. vs Axsome Therapeutics Inc.

MetricPTGX (Apr 19, 2026)AXSM (Apr 26, 2026)
Price Ratios
P/E Ratio (TTM) i139.52-50.54
Forward P/E i-244.0629.85
PEG Ratio i-1.050.79
Price to Sales (TTM) i146.9614.64
Price to Book (MRQ) i10.79105.31
Market Capitalization
Market Capitalization i$6.76B$9.51B
Enterprise Value i$6.21B$9.24B
Enterprise Value Metrics
Enterprise to Revenue i134.8514.47
Enterprise to EBITDA i-39.56-57.70
Risk & Other Metrics
Beta i2.110.47
Book Value per Share (MRQ) i$9.82$1.74

Financial Statements Comparison: Protagonist Therapeutics Inc. vs Axsome Therapeutics Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricPTGX (2025)AXSM (2025)
Revenue/Sales i46.02M638.50M
Cost of Goods Sold iN/A47.48M
COGS % of Revenue i0.0%7.4%
Gross Profit iN/A591.02M
Gross Margin i0.0%92.6%
Research & Development i159.29M183.28M
Operating Income (EBIT) i-158.13M-169.24M
Operating Margin i-343.6%-26.5%
EBITDA i-156.85M-160.17M
EBITDA Margin i-340.9%-25.1%
Pre-Tax Income i-129.31M-183.70M
Pre-Tax Income % of Revenue i-281.0%-28.8%
Income Tax i838,000-530,000
Income Tax % of Revenue i1.8%-0.1%
Net Income (Profit) i-130.15M-183.17M
Profit Margin i-282.8%-28.7%

Balance Sheet & Liquidity Metrics

MetricPTGX (2025)AXSM (2025)
Cash & Equivalents i128.39M322.93M
Total Current Assets i577.57M588.99M
Total Current Assets % of Revenue i1,255.2%92.2%
Total Current Liabilities i45.44M378.84M
Total Current Liabilities % of Revenue i98.8%59.3%
Long-Term Debt i8.04M145.13M
Long-Term Debt % of Revenue i17.5%22.7%
Total Shareholders Equity i614.71M88.30M
Retained Earnings i-470.67M-1.31B
Retained Earnings % of Revenue i-1,022.8%-204.5%
Property, Plant & Equipment i15.58M562,000

Cash Flow Statement Comparison

MetricPTGX (2025)AXSM (2025)
Operating Cash Flow i65.37M-185.86M
Operating Cash Flow % of Revenue i142.1%-29.1%
Capital Expenditures i-1.59M-480,000
Free Cash Flow i56.08M-93.89M
FCF Margin i121.9%-14.7%
Debt Repayment iN/A-334.11M
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricPTGXAXSM
Shares Short i8.63M2.83M
Short Ratio i8.934.92
Short % of Float i16.13%6.56%
Shares Outstanding i62.58M50.88M
Float Shares i51.94M43.24M
% Held by Insiders i1.23%15.47%
% Held by Institutions i113.64%76.52%
% Held by Public i-14.87%8.01%

Dividend Analysis & Yield Comparison: Protagonist Therapeutics Inc. vs Axsome Therapeutics Inc.

MetricPTGXAXSM
Last 12-Month Dividend iN/AN/A
Last 12-Month Dividend Yield iN/AN/A
3-Year Avg Annual Dividend iN/AN/A
3-Year Avg Dividend Yield iN/AN/A
3-Year Total Dividends iN/AN/A
Ex-Dividend DateN/AN/A